MedTrace Logo

A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL

NCT06314828 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-03-18

No results posted yet for this study

Summary

This is a Phase 1, open-label, single-arm study to evaluate tolerability, safety and efficacy of RJMty19 in adult subjects with r/r B-NHL.

Conditions

  • B-cell Non-Hodgkin's Lymphoma

Interventions

BIOLOGICAL

RJMty19 (CD19-CAR-DNT cells)

Lentiviral vector-transducted double negative T cells (DNT) to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide, fludarabine and Etoposide lymphodepleting chemotherapy.

Sponsors & Collaborators

  • Ruijin Hospital

    collaborator OTHER

  • Southern Medical University, China

    collaborator OTHER

  • Beijing GoBroad Hospital

    collaborator OTHER

  • Guangdong Ruishun Biotech Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-20
Primary Completion
2025-05-20
Completion
2027-05-20

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06314828 on ClinicalTrials.gov